Do you cite what you tweet? Investigating the relationship between tweeting and citing research articles

The last decade of altmetrics research has demonstrated that altmetrics have a low to moderate correlation with citations, depending on the platform and the discipline, among other factors. Most past studies used academic works as their unit of analysis to determine whether the attention they received on Twitter was a good predictor of academic engagement. Our work revisits the relationship between tweets and citations where the tweet itself is the unit of analysis, and the question is to determine if, at the individual level, the act of tweeting an academic work can shed light on the likelihood of the act of citing that same work. We model this relationship by considering the research activity of the tweeter and its relationship to the tweeted work. Results show that tweeters are more likely to cite works affiliated with their same institution, works published in journals in which they also have published, and works in which they hold authorship. It finds that the older the academic age of a tweeter the less likely they are to cite what they tweet, though there is a positive relationship between citations and the number of works they have published and references they have accumulated over time

Dynamic Regulation of Vascular Myosin Light Chain (MYL9) with Injury and Aging

Aging-associated changes in the cardiovascular system increase the risk for disease development and lead to profound alterations in vascular reactivity and stiffness. Elucidating the molecular response of arteries to injury and age will help understand the exaggerated remodeling of aging vessels.We studied the gene expression profile in a model of mechanical vascular injury in the iliac artery of aging (22 months old) and young rats (4 months old). We investigated aging-related variations in gene expression at 30 min, 3 d and 7 d post injury. We found that the Myosin Light Chain gene (MYL9) was the only gene differentially expressed in the aged versus young injured arteries at all time points studied, peaking at day 3 after injury (4.6 fold upregulation (p<0.05) in the smooth muscle cell layers. We confirmed this finding on an aging aortic microarray experiment available through NCBI's GEO database. We found that Myl9 was consistently upregulated with age in healthy rat aortas. To determine the arterial localization of Myl9 with age and injury, we performed immunohistochemistry for Myl9 in rat iliac arteries and found that in healthy and injured (30 days post injury) arteries, Myl9 expression increased with age in the endothelial layers.The consistent upregulation of the myosin light chain protein (Myl9) with age and injury in arterial tissue draws attention to the increased vascular permeability and to the age-caused predisposition to arterial constriction after balloon angioplasty

The zooarchaeological application of quantifying cranial shape differences in wild boar and domestic pigs (Sus scrofa) using 3D geometric morphometrics

Peer reviewedPublisher PD

PG-Keys: Keys for Property Graphs

International audienceWe report on a community effort between industry and academia to shape the future of property graph constraints. The standardization for a property graph query language is currently underway through the ISO Graph Query Language (GQL) project. Our position is that this project should pay close attention to schemas and constraints, and should focus next on key constraints. The main purposes of keys are enforcing data integrity and allowing the referencing and identifying of objects. Motivated by use cases from our industry partners, we argue that key constraints should be able to have different modes, which are combinations of basic restriction that require the key to be exclusive, mandatory, and singleton. Moreover, keys should be applicable to nodes, edges, and properties since these all can represent valid real-life entities. Our result is PG-Keys, a flexible and powerful framework for defining key constraints, which fulfills the above goals. PG-Keys is a design by the Linked Data Benchmark Council's Property Graph Schema Working Group, consisting of members from industry, academia, and ISO GQL standards group, intending to bring the best of all worlds to property graph practitioners. PG-Keys aims to guide the evolution of the standardization efforts towards making systems more useful, powerful, and expressive. CCS CONCEPTS • Information systems → Integrity checking; • Theory of computation → Data modeling; Database constraints theory

Graph Pattern Matching in GQL and SQL/PGQ

As graph databases become widespread, JTC1 -- the committee in joint charge of information technology standards for the International Organization for Standardization (ISO), and International Electrotechnical Commission (IEC) -- has approved a project to create GQL, a standard property graph query language. This complements a project to extend SQL with a new part, SQL/PGQ, which specifies how to define graph views over an SQL tabular schema, and to run read-only queries against them. Both projects have been assigned to the ISO/IEC JTC1 SC32 working group for Database Languages, WG3, which continues to maintain and enhance SQL as a whole. This common responsibility helps enforce a policy that the identical core of both PGQ and GQL is a graph pattern matching sub-language, here termed GPML. The WG3 design process is also analyzed by an academic working group, part of the Linked Data Benchmark Council (LDBC), whose task is to produce a formal semantics of these graph data languages, which complements their standard specifications. This paper, written by members of WG3 and LDBC, presents the key elements of the GPML of SQL/PGQ and GQL in advance of the publication of these new standards

Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial

Objectives SENECA (StEm cell iNjECtion in cAncer survivors) is a phase I, randomized, double-blind, placebo-controlled study to evaluate the safety and feasibility of delivering allogeneic mesenchymal stromal cells (allo-MSCs) transendocardially in subjects with anthracycline-induced cardiomyopathy (AIC). Background AIC is an incurable and often fatal syndrome, with a prognosis worse than that of ischemic or nonischemic cardiomyopathy. Recently, cell therapy with MSCs has emerged as a promising new approach to repair damaged myocardium. Methods The study population is 36 cancer survivors with a diagnosis of AIC, left ventricular (LV) ejection fraction ≤40%, and symptoms of heart failure (NYHA class II-III) on optimally-tolerated medical therapy. Subjects must be clinically free of cancer for at least two years with a ≤ 30% estimated five-year risk of recurrence. The first six subjects participated in an open-label, lead-in phase and received 100 million allo-MSCs; the remaining 30 will be randomized 1:1 to receive allo-MSCs or vehicle via 20 transendocardial injections. Efficacy measures (obtained at baseline, 6 months, and 12 months) include MRI evaluation of LV function, LV volumes, fibrosis, and scar burden; assessment of exercise tolerance (six-minute walk test) and quality of life (Minnesota Living with Heart Failure Questionnaire); clinical outcomes (MACE and cumulative days alive and out of hospital); and biomarkers of heart failure (NT-proBNP). Conclusions This is the first clinical trial using direct cardiac injection of cells for the treatment of AIC. If administration of allo-MSCs is found feasible and safe, SENECA will pave the way for larger phase II/III studies with therapeutic efficacy as the primary outcome

Threats posed to conservation by media misinformation

Media coverage of trophy hunting highlights the potential for misinformation to enter public and political debates on conservation issues. We argue that misinformation should be a major concern for all involved in conservation

CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly

Introduction: With an aging population there is an important need for the development of effective treatments for the amelioration of cognitive decline. Multiple mechanisms underlie age-related cognitive decline including cerebrovascular disease, oxidative stress, reduced antioxidant capacity and mitochondrial dysfunction. CoQ10 is a novel treatment which has the potential to improve brain function in healthy elderly populations due to established beneficial effects on mitochondrial function, vascular function and oxidative stress.Methods and Analysis: We describe the protocol for a 90-day randomized controlled trial which examines the efficacy of Ubiquinol (200 mg/day) vs. placebo for the amelioration of cognitive decline in a healthy (non-demented) elderly sample, aged 60 years and over. The primary outcome is the effect of Ubiquinol at 90 days compared to baseline on CogTrack composite measures of cognition. Additional cognitive measures, as well as measures of cardiovascular function, oxidative stress, liver function and mood will also be monitored across 30-, 60- and 90- day time points. Data analyses will involve repeated measures analysis of variance (ANOVA).Discussion: This study will be the first of its kind to provide important clinical and mechanistic data regarding the efficacy of Ubiquinol as a treatment for age-related cognitive decline in the healthy elderly with important implications for productivity and quality of life within this age group.Clinical Trial Registration: The trial has been registered with the Australian and New Zealand Clinical Trials Registry (ANZCTRN12618001841268)

The Linked Data Benchmark Council (LDBC): Driving competition and collaboration in the graph data management space

Graph data management is instrumental for several use cases such as recommendation, root cause analysis, financial fraud detection, and enterprise knowledge representation. Efficiently supporting these use cases yields a number of unique requirements, including the need for a concise query language and graph-aware query optimization techniques. The goal of the Linked Data Benchmark Council (LDBC) is to design a set of standard benchmarks that capture representative categories of graph data management problems, making the performance of systems comparable and facilitating competition among vendors. LDBC also conducts research on graph schemas and graph query languages. This paper introduces the LDBC organization and its work over the last decade

Randomized placebo-controlled trial on azithromycin to reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocol

Background: Acute lower respiratory infections are the commonest cause of morbidity and potentially preventable mortality in Indigenous infants. Infancy is also a critical time for post-natal lung growth and development. Severe or repeated lower airway injury in very young children likely increases the likelihood of chronic pulmonary disorders later in life. Globally, bronchiolitis is the most common form of acute lower respiratory infections during infancy. Compared with non-Indigenous Australian infants, Indigenous infants have greater bacterial density in their upper airways and more severe bronchiolitis episodes. Our study tests the hypothesis that the anti-microbial and anti-inflammatory properties of azithromycin, improve the clinical outcomes of Indigenous Australian infants hospitalised with bronchiolitis.Methods: We are conducting a dual centre, randomised, double-blind, placebo-controlled, parallel group trial in northern Australia. Indigenous infants (aged ≤ 24-months, expected number = 200) admitted to one of two regional hospitals (Darwin, Northern Territory and Townsville, Queensland) with a clinical diagnosis of bronchiolitis and fulfilling inclusion criteria are randomised (allocation concealed) to either azithromycin (30 mg/kg/dose) or placebo administered once weekly for three doses. Clinical data are recorded twice daily and nasopharyngeal swab are collected at enrolment and at the time of discharge from hospital. Primary outcomes are 'length of oxygen requirement' and 'duration of stay,' the latter based upon being judged as 'ready for respiratory discharge'. The main secondary outcome is readmission for a respiratory illness within 6-months of leaving hospital. Descriptive virological and bacteriological (including development of antibiotic resistance) data from nasopharyngeal samples will also be reported.Discussion: Two published studies, both involving different patient populations and settings, as well as different macrolide antibiotics and treatment duration, have produced conflicting results. Our randomised, placebo-controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian Indigenous infants who are at high risk of developing chronic respiratory illness. If azithromycin is efficacious in reducing the morbidly of Indigenous infants hospitalised with bronchiolitis, the intervention would lead to improved short term (and possibly long term) health benefits. Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12610000326099